Cargando…

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia

BACKGROUND: Eltrombopag (EPAG), an oral thrombopoietin receptor agonist (TPO-RA), has been proven to improve the hematologic response without increasing toxic effects as a first-line therapy combined with standard immunosuppressive treatment (IST) in adults with severe aplastic anemia (SAA). Neverth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yufei, Yang, Wenrui, Zhao, Xin, Hu, Xiangrong, Hu, Jing, Liu, Xu, Li, Jianping, Ye, Lei, Xiong, Youzhen, Yang, Yang, Zhang, Baohang, Li, Xiaoxia, Yang, Xiawan, Shi, Yimeng, Peng, Guangxin, Li, Yuan, Fan, Huihui, Zhou, Kang, Jing, Liping, Zhang, Li, Zhang, Fengkui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872003/ https://www.ncbi.nlm.nih.gov/pubmed/36704148 http://dx.doi.org/10.3389/fped.2022.1095143

Ejemplares similares

Genotype-degree of hemolysis correlation in hereditary spherocytosis
por: Shi, Yimeng, et al.
Publicado: (2023)

Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study
por: Yang, Wenrui, et al.
Publicado: (2023)

Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia
por: Liu, Xu, et al.
Publicado: (2023)

Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study
por: Yang, Wenrui, et al.
Publicado: (2023)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag
por: Zaimoku, Yoshitaka, et al.
Publicado: (2021)

Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
por: Liu, Limin, et al.
Publicado: (2022)

Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag
por: Li, Ruixin, et al.
Publicado: (2022)

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
por: Goronkova, Olga, et al.
Publicado: (2022)

Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis−associated aplastic anemia
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis
por: Zhu, Yangmin, et al.
Publicado: (2020)

P811: A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN
por: yang, B., et al.
Publicado: (2022)

Eltrombopag for the treatment of aplastic anemia: current perspectives
por: Lum, Su Han, et al.
Publicado: (2016)

Aplastic Anemia Treated with Eltrombopag during Pregnancy
por: Suminaga, Yuri, et al.
Publicado: (2022)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
por: Wan, Ziqi, et al.
Publicado: (2023)

Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis
por: Zhang, Senlin, et al.
Publicado: (2023)

P820: PREDICTING RESPONSE TO RABBIT ATG-BASED INTENSIVE IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG IN CHINESE ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Li, R., et al.
Publicado: (2022)

Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China
por: Zhang, Zhuxin, et al.
Publicado: (2023)

Iron Deficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Cross-Sectional Survey from a Single Institution in China
por: Peng, Guangxin, et al.
Publicado: (2018)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
por: Zhang, Zhuxin, et al.
Publicado: (2023)

Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan
por: Imada, Kazunori, et al.
Publicado: (2020)

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Prabahran, Ashvind, et al.
Publicado: (2023)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
por: Konishi, Akiko, et al.
Publicado: (2019)

Current evidence and the emerging role of eltrombopag in severe aplastic anemia
por: Drexler, Beatrice, et al.
Publicado: (2021)

Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial
por: Ji, Jiang, et al.
Publicado: (2023)

A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy
por: Peng, Guangxin, et al.
Publicado: (2022)

Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China
por: Zuo, Wei, et al.
Publicado: (2020)

Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series
por: Martynova, Anastasia, et al.
Publicado: (2021)

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
por: Lengline, Etienne, et al.
Publicado: (2018)

PB1941: PRELIMINARY EXPLORATION OF PROLONGED USE OF ELTROMBOPAG IN PATIENTS WITH NAÏVE SEVERE APLASTIC ANEMIA IN THE REAL WORLD: DURATION AND EFFICACY
por: Li, R., et al.
Publicado: (2022)

Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia
por: Kelly, Darren, et al.
Publicado: (2020)

PB2479: ELTROMBOPAG, BUT NOT AVATROMBOPAG, REGULATES BONE MARROW MICROENVIRONMENT MIMICKING APLASTIC ANEMIA THROUGH DOWN-REGULATION OF FERROPTOSIS INHIBITOR
por: Ji, Jiang, et al.
Publicado: (2023)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
por: Chang, H., et al.
Publicado: (2022)

Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia
por: Chen, Hai-Fei, et al.
Publicado: (2014)

A multicentre trial of intensive immunosuppressive therapy combined with umbilical cord blood for the treatment of severe aplastic anaemia
por: Zhou, Fang, et al.
Publicado: (2022)

P766: ELTROMBOPAG EFFECTIVELY ALLEVIATES APLASTIC ANEMIA THROUGH REDUCING AKT PROTEIN STABILITY AND MODULATING T LYMPHOCYTE SUBSETS
por: Lin, Zenghua, et al.
Publicado: (2023)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013)

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
por: Tremblay, Gabriel, et al.
Publicado: (2019)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
por: Guan, Yihong, et al.
Publicado: (2022)

The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review
por: Marrapodi, Maria Maddalena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_olrea158lpi512vlsr35ua3psn